Thymulin half-life & pharmacokinetics

Reported half-life

Short plasma half-life (minutes) for the free peptide; zinc binding stabilises the bioactive form. Functional immune-modulatory effects persist substantially longer through downstream effects on T-cell function. Pre-clinical protocols typically use subcutaneous or intraperitoneal daily administration to maintain therapeutic exposure.

The half-life and pharmacokinetic profile of Thymulin reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (research; standard route)
• Intraperitoneal injection (pre-clinical research)
• Intramuscular injection (limited early clinical exploration)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Endogenous nonapeptide thymic hormone; zinc-dependent immune-modulator with T-cell maturation and Th1-polarising effects.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Thymulin acts as follows:

Thymulin is a 9-amino-acid endogenous peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) originally characterised by Jean-François Bach and colleagues at the Necker Hospital in Paris in the 1970s as the principal endogenous factor in serum responsible for thymus-dependent lymphocyte differentiation — originally named 'Facteur Thymique Sérique' (FTS). The peptide is produced by thymic epithelial cells and circulates in plasma, exerting endocrine effects on T-cell development and peripheral immune function.

See the full Thymulin research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.